These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

339 related articles for article (PubMed ID: 17495867)

  • 1. HMG-CoA reductase inhibitors and the kidney.
    Campese VM; Park J
    Kidney Int; 2007 Jun; 71(12):1215-22. PubMed ID: 17495867
    [TBL] [Abstract][Full Text] [Related]  

  • 2. HMG-CoA reductase inhibitors and the kidney.
    Campese VM; Hadaya B; Chiu J
    Curr Hypertens Rep; 2005 Oct; 7(5):337-42. PubMed ID: 16157074
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The dyslipidemia of chronic renal disease: effects of statin therapy.
    Ozsoy RC; van Leuven SI; Kastelein JJ; Arisz L; Koopman MG
    Curr Opin Lipidol; 2006 Dec; 17(6):659-66. PubMed ID: 17095911
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Effects of statins on renal function.
    Agarwal R
    Mayo Clin Proc; 2007 Nov; 82(11):1381-90. PubMed ID: 17976359
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Statins in chronic kidney disease and kidney transplantation.
    Kassimatis TI; Goldsmith DJ
    Pharmacol Res; 2014 Oct; 88():62-73. PubMed ID: 24995940
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The role of statins in chronic kidney disease.
    Kalaitzidis RG; Elisaf MS
    Am J Nephrol; 2011; 34(3):195-202. PubMed ID: 21791915
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Do HMG-CoA reductase inhibitors improve kidney function? The saga continues.
    Campese VM; Ku E; Bigazzi R; Bianchi S
    J Nephrol; 2011; 24(5):550-3. PubMed ID: 21887675
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Chronic kidney disease and statins].
    Matovinović MS
    Lijec Vjesn; 2006; 128(11-12):345-50. PubMed ID: 17212196
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Effects of statin therapy on the progression of chronic kidney disease.
    Shah S; Paparello J; Danesh FR
    Adv Chronic Kidney Dis; 2005 Apr; 12(2):187-95. PubMed ID: 15822054
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Statin treatment for dyslipidemia in chronic kidney disease and renal transplantation: a review of the evidence.
    Kanbay M; Turgut F; Covic A; Goldsmith D
    J Nephrol; 2009; 22(5):598-609. PubMed ID: 19809992
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Cross-talk between statins and PPARalpha in cardiovascular diseases: clinical evidence and basic mechanisms.
    Paumelle R; Staels B
    Trends Cardiovasc Med; 2008 Apr; 18(3):73-8. PubMed ID: 18436144
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Statins and kidney disease].
    Bigazzi R; Grimaldi D; Bianchi S
    G Ital Nefrol; 2012; 29(2):160-73. PubMed ID: 22538946
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Dyslipidemia, statins, and CKD patients' outcomes - review of the evidence in the post-sharp era.
    Heymann EP; Kassimatis TI; Goldsmith DJ
    J Nephrol; 2012; 25(4):460-72. PubMed ID: 22641572
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Dyslipidemia in chronic kidney disease: are statins still indicated in reduction cardiovascular risk in patients on dialysis treatment?
    Scarpioni R; Ricardi M; Melfa L; Cristinelli L
    Cardiovasc Ther; 2010 Dec; 28(6):361-8. PubMed ID: 20553296
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Effects of statins on renal function.
    Agarwal R
    Am J Cardiol; 2006 Mar; 97(5):748-55. PubMed ID: 16490450
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Modulation of heat shock proteins by statins.
    Forouzanfar F; Butler AE; Banach M; Barreto GE; Sahbekar A
    Pharmacol Res; 2018 Aug; 134():134-144. PubMed ID: 29935271
    [TBL] [Abstract][Full Text] [Related]  

  • 17. HMG CoA reductase inhibitors and renoprotection: the weight of the evidence.
    Romayne Kurukulasuriya L; Athappan G; Saab G; Whaley Connell A; Sowers JR
    Ther Adv Cardiovasc Dis; 2007 Oct; 1(1):49-59. PubMed ID: 19124395
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Pleiotropic effects of statins: evidence against benefits beyond LDL-cholesterol lowering.
    Pedersen TR
    Am J Cardiovasc Drugs; 2010; 10 Suppl 1():10-7. PubMed ID: 21391729
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Dyslipidemia as a therapeutic target for prevention of cardiovascular events and end-stage renal disease].
    Watanabe T
    Nihon Rinsho; 2008 Sep; 66(9):1761-9. PubMed ID: 18788407
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Statins in chronic renal disease].
    Ferreira SR; Rocha AM; Saraiva JF
    Arq Bras Cardiol; 2005 Oct; 85 Suppl 5():45-9. PubMed ID: 16400399
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 17.